Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing
Cells · 01.02.2023 · 12 (3) · 472
DOI: 10.3390/cells12030472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 01.02.2023. Verfasst von Lorenz M Brunner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland. Hauptthemen laut MEDLINE: Lymphangiogenesis, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, European Research Council, ETH Zurich.
Themen: Wundversorgung
Abstract (Originalsprache)
Chronic wounds represent a major therapeutic challenge. Lymphatic vessel function is impaired in chronic ulcers but the role of lymphangiogenesis in wound healing has remained unclear. We found that lymphatic vessels are largely absent from chronic human wounds as evaluated in patient biopsies. Excisional wound healing studies were conducted using transgenic mice with or without an increased number of cutaneous lymphatic vessels, as well as antibody-mediated inhibition of lymphangiogenesis. We found that a lack of lymphatic vessels mediated a proinflammatory wound microenvironment and delayed wound closure, and that the VEGF-C/VEGFR3 signaling axis is required for wound lymphangiogenesis. Treatment of diabetic mice (db/db mice) with the F8–VEGF-C fusion protein that targets the alternatively spliced extra domain A (EDA) of fibronectin, expressed in remodeling tissue, promoted wound healing, and potently induced wound lymphangiogenesis. The treatment also reduced tissue inflammation and exerted beneficial effects on the wound microenvironment, including myofibroblast density and collagen deposition. These findings indicate that activating the lymphatic vasculature might represent a new therapeutic strategy for treating chronic non-healing wounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland.
- Institute for Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
- Philochem AG, 8112 Otelfingen, Switzerland.
- Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland.
ORCID-Profile: Lorenz M Brunner, Yuliang He, Nikola Cousin, Livia K Albin, Gaetana Restivo, Sabine Werner, Michael Detmar
Förderung
- Swiss National Science Foundation
- European Research Council
- ETH Zurich
Zitieren
APA
Brunner, L. M., He, Y., Cousin, N., Scholl, J., Albin, L. K., Schmucki, B., Supersaxo, S., Restivo, G., Hafner, J., Neri, D., Werner, S., & Detmar, M. (2023). Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing. Cells, 12(3), 472. https://doi.org/10.3390/cells12030472
Vancouver
Brunner LM, He Y, Cousin N, Scholl J, Albin LK, Schmucki B, et al. Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing. Cells. 2023;12(3):472. doi:10.3390/cells12030472
BibTeX
@article{Brunner2023,
author = {Brunner, Lorenz M and He, Yuliang and Cousin, Nikola and Scholl, Jeannette and Albin, Livia K and Schmucki, Bianca and Supersaxo, Sandrin and Restivo, Gaetana and Hafner, Jürg and Neri, Dario and Werner, Sabine and Detmar, Michael},
title = {Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing},
journal = {Cells},
year = {2023},
volume = {12},
number = {3},
pages = {472},
doi = {10.3390/cells12030472}
}
EUVIMED